- Insulin lispro
drugbox
IUPAC_name =
CAS_number = 133107-64-9
ATC_prefix = A10
ATC_suffix = AB04
PubChem = 16132438
DrugBank = BTD00065
chemical_formula =
C=257|H=389|N=65|O=77|S=6
molecular_weight = 5813.63 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US = C
pregnancy_category=
legal_AU =
legal_CA =
legal_UK = POM
legal_US = Rx-only
legal_status =
routes_of_administration = SubcutaneousInsulin lispro (marketed by Lilly as "Humalog") is a fast acting
insulin analogue ; it was the first insulin analogue.It was engineered through
recombinant DNA technology so that the penultimatelysine andproline residues on the C-terminal end of the B-chain were reversed. This modification did not alter receptor binding, but blocked the formation of insulindimer s and hexamers. This allowed larger amounts of active monomeric insulin to be available forpostprandial (after meal) injections. [cite web |url=http://www.aafp.org/afp/980115ap/noble.html |title=Insulin Lispro:A Fast-Acting Insulin Analog |accessdate=2007-06-08 |format= |work= ]It has been shown by Shimoda et al. that, when comparing three insulin delivery methods, i.v. (intravenous) regular insulin, s.c. (subcutaneous) insulin Lispro, and s.c. regular insulin, that s.c. insulin Lispro performs almost as well as i.v. regular insulin in handling meal disturbances. S.c. regular insulin performed worse than s.c. insulin lispro, resulting in
postprandial glucose peaks, in addition to postprandial hypoglycemia.References
Wikimedia Foundation. 2010.